Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Treatment with high-dose ondansetron shows no effect on sensory phenomena (SP) in patients with obsessive-compulsive disorder (OCD), according to a study.

Ondansetron plus SRI eases OCD severity

Radiotherapy plus short-course ADT confers survival benefit in oligometastatic prostate cancer

In patients with oligometastatic hormone-sensitive prostate cancer, the combination of stereotactic body radiotherapy (SBRT) plus a short course of androgen deprivation therapy (ADT) appears to improve progression-free survival (PFS), according to the phase II RADIOSA trial.

Radiotherapy plus short-course ADT confers survival benefit in oligometastatic prostate cancer

Japanese adults with obesity lose weight with once-weekly tirzepatide

Taking tirzepatide once a week appears to result in clinically meaningful reductions in body weight for Japanese adults with obesity, according to the results of the phase III multicentre SURMOUNT-J trial

Japanese adults with obesity lose weight with once-weekly tirzepatide

Allergy history, previous exposure predict oxaliplatin hypersensitivity reactions

A history of allergy, previous oxaliplatin exposure, and chemotherapy regimens are associated with a higher risk of oxaliplatin hypersensitivity reactions in patients with colorectal cancer, reveals a study.

Allergy history, previous exposure predict oxaliplatin hypersensitivity reactions

Cúm mùa: Gánh nặng và giải pháp

Hãy cùng nhìn lại những nghiên cứu, sáng kiến và nỗ lực không ngừng của Sanofi trong công cuộc bảo vệ sức khỏe cộng đồng trước cúm mùa trong bài viết này.

Cúm mùa: Gánh nặng và giải pháp

Original New Drug Application Approvals by US FDA (1-15 February 2025)

New drug applications approved by US FDA as of 1-15 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 February 2025)

Adjuvant nivolumab delivers in muscle-invasive bladder cancer

09 Mar 2025 bởi

Adjuvant nivolumab appears to improve survival outcomes in patients with muscle-invasive bladder cancer (MIBC) who have undergone radical surgery, regardless of prior exposure to neoadjuvant chemotherapy, according to additional data from the phase III CheckMate 274 trial.

Adjuvant nivolumab delivers in muscle-invasive bladder cancer

09 Mar 2025

Tetracycline trumps macrolide in MRMP pneumonia

Tetracycline demonstrates superior clinical efficacy to that of macrolide in children with macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia, a study has shown.

Tetracycline trumps macrolide in MRMP pneumonia

Sustained PFS benefit in breast cancer with palbociclib + exemestane with ovarian function suppression

Treatment with palbociclib plus exemestane with ovarian function suppression does not appear to produce improvements in overall survival (OS), although it yields sustained increases in progression-free survival (PFS) as compared with capecitabine in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer, according to updated data from the phase II Young-PEARL study.

Sustained PFS benefit in breast cancer with palbociclib + exemestane with ovarian function suppression